Biotron Limited · ASX:BIT
Biotron — Australia Biotech Invest and Partnering 2019
13 slides from Biotron's conference presentation, Oct 31, 2019
Slide 1: Presentation to Investors
Level 2, 66 Hunter Street Sydney NSW 2000 Tel: (61-2) 9300 3344 Fax: (61-2) 9221 6333 E-mail: pnightingale@biotron.com.au Website: www.biotron.com.au 31 October 2019 The Manager Companies ASX Limited 20 Bridge Street Sydney NSW 2000 (13 pages by email) Dear Madam PRESENTATION TO INVESTORS I attach a
Slide 2: Biotron Limited (ASX:BIT) Investor Update
BIOTRON LIMITED (ASX:BIT) Investor Update October 2019
Slide 3: Forward Looking Statements
Forward Looking Statements This presentation may contain forward-looking statements with respect to the financial condition, results and business achievements/performance of Biotron Limited (ACN 086 399 144) and certain of the plans and objectives of its management. These statements are statements t
Slide 4: Summary
Summary • Unique antiviral drugs targeting big health problems: HIV-1, Hepatitis B, Hepatitis C, Dengue and others • Phase 2 BIT225 HIV-1 clinical trial induced key immune responses not seen in patients dosed with approved anti- HIV-1 drugs • World-first: BIT225 targets HIV-1 in long-lived reservoir
Slide 5: Overview
Overview • Clinical stage drug development company • Robust pipeline of drugs targeting serious virus infections • Focused on the design and development of a new class of antiviral drugs targeting viral-encoded viroporin proteins • Lead candidate BIT225 is a novel, first-in-class, oral small molecul
Slide 6: Key Achievements 2018/2019
Key Achievements 2018/2019 • Completed Phase 2 HIV-1 clinical trial of BIT225 • Reported positive results from the Phase 2 HIV-1 clinical trial • Raised $5.7 million after costs in late 2018, including $4.7 million for 30 Nov ‘18 $0.06 options • Places the company in a sound financial position as it
Slide 7: HIV-1 Eradication
HIV-1 Eradication Current drugs do not cure HIV-1 infection • HIV-1 remains hidden in reservoirs, leading to chronic, life-long infection • Invisible to body’s immune defences • Not sensitive to current anti-HIV-1 drugs • New mode of actions drugs are needed to eradicate or cure HIV-1 infection Why
Slide 8: BIT225-009 Phase 2 HIV-1 Trial
BIT225-009 Phase 2 HIV-1 Trial AIM – to determine whether BIT225 has a clinical benefit over and above current anti- HIV-1 drugs, and provide data to inform the drug’s future development path Phase 2, 36 subject trial (placebo controlled, double-blinded, multi-site trial) - HIV-1 positive, treatment
Slide 9: Significance of Results from BIT225-009 Trial
Significance of Results from BIT225-009 Trial Data from the Phase 2 trial showed that BIT225 induced: 1. Statistically significant reduction in immune activation (sCD163) 2. Significantly significant changes in specific immune cell markers i.e. BIT225, a small molecule, direct-acting antiviral drug
Slide 10: Hepatitis B Virus
Hepatitis B Virus • ~300 million worldwide chronically infected with HBV • HBV causes up to 80% of liver cancers (5 year survival of 15%) • >780,000 die every year as a consequence of HBV infection • Current treatments suppress virus replication but do not deliver a cure • Hepatitis B virus (HBV) th
Slide 11: Commercialisation & Outlook for 2019/2020 FY
Commercialisation & Outlook for 2019/2020 FY • Prime focus is partnering the HIV-1 program • Progressing discussions with potential partners • Ongoing analyses of clinical trial samples is adding to the data package/IP position • Conferring with KOLs/advisory group to map out late-stage clinical dev
Slide 12: Financial Information
Financial Information Key Financial Metrics Ticker Code ASX: BIT Share Price (28/10/19) A $0.075 Market Cap A $44 million 12 Month Trading Range A $0.055 – 0.30 Shares Outstanding 596.05 million Options (BITO) 116 million $0.05 expiry 12/12/19 Cash Position (09/2019) A $4.86 million Monthly Cash Bur
Slide 13: Biotron Limited (ASX:BIT)
BIOTRON LIMITED (ASX:BIT) Michelle Miller Managing Director mmiller@biotron.com.au www.biotron.com.au
Biotron — Australia Biotech Invest and Partnering 2019 on 6ix